Graham Goodrich, CCO, Apnimed, outlines how advances in diagnostics, growing recognition of sleep apnea’s systemic impact, and emerging oral therapies are driving renewed momentum in sleep medicine as Apnimed advances toward commercialization.Pharmaceutical Executive; As you arrive this year at The J.P. Morgan Healthcare Conference what signals are you seeing around renewed interest in sleep medicine, […]
